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Introduction: Systemic sclerosis (SSc) is a severe and
costly multiorgan autoimmune connective tissue
disease characterised by vasculopathy and fibrosis.
One of the major causes of SSc-related death is
pulmonary arterial hypertension (PAH), which develops
in 12–15% of patients with SSc and accounts for 30–
40% of deaths. In situ thrombosis in the small calibre
peripheral pulmonary vessels resulting from endothelial
dysfunction and an imbalance of anticoagulant and
prothrombotic mediators has been implicated in the
complex pathophysiology of SSc-related PAH (SSc-
PAH), with international clinical guidelines
recommending the use of anticoagulants for some
types of PAH, such as idiopathic PAH. However,
anticoagulation has not become part of standard
clinical care for patients with SSc-PAH as only
observational evidence exists to support its use.
Therefore, we present the rationale and methodology of
a phase III randomised controlled trial (RCT) to
evaluate the efficacy, safety and cost-effectiveness of
anticoagulation in SSc-PAH.
Methods and analysis: This Australian multicentre
RCT will compare 2.5 mg apixaban with placebo, in
parallel treatment groups randomised in a 1:1 ratio,
both administered twice daily for 3 years as adjunct
therapy to stable oral PAH therapy. The composite
primary outcome measure will be the time to death or
clinical worsening of PAH. Secondary outcomes will
include functional capacity, health-related quality of life
measures and adverse events. A cost-effectiveness
analysis of anticoagulation versus placebo will also be
undertaken.
Ethics and dissemination: Ethical approval for this
RCT has been granted by the Human Research Ethics
Committees of all participating centres. An independent
data safety monitoring board will review safety and
tolerability data for the duration of the trial. The
findings of this RCT are to be published in open
access journals.
Trial registration number: ACTRN12614000418673,
Pre-results.
Strengths and limitations of this study
▪ This is the first clinical trial ever to evaluate the
efficacy, safety and cost-effectiveness of anticoa-
gulation as adjunct treatment in systemic
sclerosis-related pulmonary arterial hypertension
(PAH).
▪ The blinded randomised placebo-controlled
design of this trial is intended to minimise bias.
▪ The choice of apixaban 2.5 mg two times a day
as the anticoagulant treatment is based on con-
sideration of the risk to benefit ratio in systemic
sclerosis-related PAH. However, this study is not
intended to specifically evaluate the efficacy,
safety and costeffectiveness of other anticoagu-
lant doses or drugs in this condition.
▪ The use of a composite clinical worsening
primary end point and health-related quality of
life as a secondary end point is in line with the
most recent expert taskforce recommendations.
▪ Among the limitations of this study is the inclu-
sion of patients with PAH of varying durations
and not exclusively incident cases, and the use
of self-reported health service usage in cost-
effectiveness analysis. In addition, indirect costs
are not quantified.
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INTRODUCTION
Scleroderma or systemic sclerosis (SSc) is a multiorgan
autoimmune connective tissue disease (CTD) charac-
terised by vasculopathy and ﬁbrosis, which is estimated
to affect over 2 million people worldwide, with some
studies indicating a rising incidence.1–3 Owing to the
multiorgan nature and chronicity of the disease, SSc is
associated with signiﬁcant morbidity and is one of the
most costly rheumatic diseases.4–7 SSc is also a life-
threatening condition that carries the greatest burden of
case-based mortality among the rheumatic diseases,
reducing life expectancy by an average of 16 years per
male patient and 34.1 years per female patient.8 It is
now well established that pulmonary arterial hyperten-
sion (PAH), a condition of increased resistance in the
pulmonary vasculature, is one of the leading causes of
death in SSc, accounting for 30–40% of deaths in this
disease.9–13 Untreated, SSc-related PAH (SSc-PAH) may
follow a rapidly fatal course, with death resulting from
right ventricular failure and arrhythmias.9
So-called ‘advanced’ PAH therapies target mediators
of the complex pathophysiology underlying PAH
(ﬁgure 1), predominantly molecules responsible for vas-
cular remodelling, that result in an imbalance between
endogenous pulmonary vasoconstriction and vasodila-
tion.14 15 In SSc-PAH, these advanced PAH therapies
demonstrate improved survival, exercise capacity as mea-
sured by 6 min walk distance (6MWD) and
health-related quality of life (HRQoL) outcomes, com-
pared with placebo.14–16 Prior to the advent of advanced
PAH therapies in the early 2000s, the 1-year survival of
patients with SSc-PAH was 45%.17 Subsequently, a system-
atic review of all randomised controlled trials (RCTs) of
advanced PAH therapies, including patients with
primary ‘idiopathic’ PAH (iPAH) and PAH secondary to
CTD (CTD-PAH), reported an absolute reduction in
mortality of 39% (p=0.04) with speciﬁc PAH treatment
compared with placebo.18 Further, two Australian obser-
vational studies have shown improved survival with com-
bination PAH therapy compared with monotherapy in
patients with iPAH and CTD-PAH (3-year survival 85%
with combination therapy vs 60% with monotherapy in
CTD-PAH).19 20 Thus, survival has improved dramatically
since the introduction of advanced therapies. However,
PAH still carries a high burden of morbidity and mortal-
ity.10 15 Importantly, SSc-PAH continues to display the
poorest prognosis compared with iPAH and other
CTD-PAH subgroups.21 22
In situ thrombosis is a likely contributor to the patho-
physiology of SSc-PAH, with pulmonary vascular (venous
and arterial) thrombosis in the small calibre peripheral
pulmonary vessels appearing as a common histological
feature in both iPAH and CTD-PAH tissue specimens
(ﬁgure 2).23–25 While several observational studies,
including the Australian Scleroderma Cohort Study, have
suggested a survival beneﬁt with anticoagulation in PAH,
other observational studies have not supported this
ﬁnding.19 26–31 However, many of the patients included
in these studies were not on advanced PAH therapy, and
the majority had iPAH.28 31 In contrast, the Australian
Scleroderma Cohort Study data revealed a substantial
survival beneﬁt with anticoagulation when administered
in conjunction with advanced PAH therapy.19 In this
CTD-PAH cohort (95% of whom were patients with
SSc-PAH), exhibiting a median survival of only 5 years,
an estimated 5-fold reduction in mortality was observed
with warfarin treatment, prescribed at physician discre-
tion, over an average 2.6±1.8 years follow-up.19
Furthermore, in contrast to the support for
Figure 1 The pathophysiological targets of advanced PAH
therapies. Pulmonary artery endothelial cell dysfunction
impacts on vascular smooth muscle cell tone and remodelling
in the following ways, targeted by the three main classes of
advanced PAH therapy to prevent (–) or promote (+) the
physiological mechanisms described in the centre of the
diagram: (+++) overexpression of ET-1 has a potent
vasoconstrictor effect. Thus, ETRAs such as bosentan and
ambrisentan block vasoconstriction of pulmonary artery
smooth muscle cells. (φφφ) Impaired production of NO is
remedied by PDE-5 inhibitors such as sildenafil that enhance
NO-mediated vasodilation. (---) Prostacyclin is a vasodilator
with antiproliferative effects that is deficient in the setting of
PAH. Prostacyclin analogues such as epoprostenol,
treprostinil and iloprost therefore promote vasodilation in
pulmonary smooth muscle cells and prevent vascular
remodelling which may involve numerous cells, including
platelets and fibroblasts. ET-1, endothelin-1; ETRA, ET-1
receptor antagonist; NO, nitric oxide; PAH, pulmonary arterial
hypertension; PDE-5, phosphodiesterase type-5.
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anticoagulation in European and American guidelines
for treatment of iPAH, owing to the absence of RCT
data, recommendations for anticoagulation in SSc-PAH
are based on weak evidence and reﬂect a state of clinical
equipoise among experts.32–36 Although pulmonary vas-
cular pathobiology may be similar to that seen in iPAH,
patients with SSc-PAH have other clinical features which
may impact the risk to beneﬁt ratio of anticoagulation.
Hence, there is great variability in beliefs and prescribing
habits regarding anticoagulation as adjunct therapy in
SSc-PAH.26 37 The weight of preliminary evidence, soci-
etal costs and high morbidity of SSc-PAH demand an
urgent resolution of this contentious issue through an
RCT.
In the design of this RCT, several considerations
favour the use of novel oral anticoagulants as safer, more
effective and more convenient than warfarin for patients
with SSc-PAH. Factor Xa is a pivotal component of the
coagulation cascade, and oral factor Xa inhibitors such
as apixaban and rivaroxaban, which are hypothesised to
have antiplatelet and endothelial effects, may target mul-
tiple pathways critical to SSc-PAH pathogenesis.38–41 Oral
factor Xa inhibitors may offer more stable blood levels
than warfarin, assuming full compliance. These agents
are administered at ﬁxed doses, have fewer diet or drug
interactions, are eliminated through multiple pathways
and do not require routine international normalised
ratio (INR) monitoring.38 39 The reliable bioavailability
of the factor Xa inhibitors is particularly advantageous
in patients with SSc, many of whom have gut hypomoti-
lity and bacterial overgrowth, which may affect warfarin
and vitamin K absorption, resulting in unstable INRs.42
With up to 6% of patients with SSc exhibiting intestinal
telangiectasiae or gastric antral vascular ectasiae which
may bleed,43 44 the lower risk of gastrointestinal bleeding
with apixaban, observed in large clinical trials of other
patient groups, is reassuring.45–53 Finally, patients with
SSc often have difﬁcult venous access due to skin ﬁbrosis
and subcutaneous joint contractures.26 Such patients are
typically reluctant to have the multiple venesections
required for INR monitoring. Since oral factor Xa inhi-
bitors do not require monitoring of blood levels and
dose adjustment,38 39 there is potential to blind treat-
ment assignment for RCTs and participant retention in
clinical trials could possibly increase.
Objective
The aim of this study is to evaluate the efﬁcacy, safety
and cost-effectiveness of treatment over 3 years with the
novel oral anticoagulant apixaban (a factor Xa inhibi-
tor) in SSc-PAH, by undertaking a multicentre, double-
blind, placebo-controlled RCT. The intervention will
occur on a background of advanced PAH therapy pre-
scribed as standard of care for participants assigned to
treatment and placebo arms.
METHODS AND ANALYSIS
Study design
The study is designed as a multicentre, participant-
blinded and investigator-blinded, placebo-controlled
phase III clinical trial to compare the efﬁcacy, safety and
cost-effectiveness of apixaban 2.5 mg twice daily versus
placebo, randomised in a 1:1 ratio, over a treatment
period of 3 years, as additional therapy in patients with
SSc-PAH who are already on advanced pulmonary vaso-
dilators. The study design and assessment timeline is
illustrated in ﬁgure 3.
Study population
Study participants will be identiﬁed by cardiologists,
rheumatologists and respirologists during the course of
routine care at 13 Australian PAH treatment centres
across six states (New South Wales, Queensland, South
Australia, Tasmania, Victoria and Western Australia).
Recruitment will take place over 24 months or until
sample size requirements are met and participants will
be treated for 36 months. Participants will be adult men
and women with symptomatic SSc-PAH as deﬁned by the
American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) 2013 classiﬁcation
criteria for SSc54 and international guidelines for diag-
nosis of PAH.35 54 Inclusion and exclusion criteria are
listed in tables 1 and 2, respectively. Many of the exclu-
sion criteria focus on reducing the risk of adverse bleed-
ing events in the study population.44 50 All eligible
participants will sign informed consent prior to study
enrolment, following adequate explanation of the aims,
methods, objectives and potential hazards of the trial by
the responsible investigator.
Randomisation and allocation concealment
Ethical considerations mandate background treatment
with advanced PAH therapies as standard of care in all
study participants.35 36 Since sites differ in rates of use of
PAH-speciﬁc therapies, including combination therapy,
randomisation will be stratiﬁed according to site, with
the effect of various PAH therapies subsequently
adjusted for in multiple regression analysis.
Figure 2 The pathogenic triad of systemic sclerosis-related
PAH. Vasoconstriction, vascular remodelling and thrombosis
constitute the pathogenic ‘triad’ of PAH in SSc (SSc-PAH).
The ETRAs, PDE-5 inhibitors and prostacyclin promote
vasodilation and prevent vascular remodelling, while
anticoagulants may have a beneficial effect in SSc-PAH by
preventing thrombosis. ETRA, endothelin receptor antagonist;
PAH, pulmonary arterial hypertension; PDE-5,
phosphodiesterase type-5; SSc, systemic sclerosis.
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Randomisation to placebo or study drug in a 1:1 ratio
will be performed by a statistician who is not associated
with any study site, using computer-generated block ran-
domisation, stratiﬁed according to study site. After the
investigator obtains informed consent and conﬁrms eli-
gibility, patients who meet all inclusion criteria and
none of the exclusion criteria will be assigned to study
treatment by the site pharmacist at baseline visit, accord-
ing to the site randomisation schedule.
Participants, healthcare providers, investigators, data
collectors and outcome assessors will be blinded to treat-
ment assignment. To ensure allocation concealment, the
appearance of the investigational drug (apixaban,
BMS-562247, Bristol-Myers Squibb Limited (BMS)) and
its packaging will be indistinguishable from the match-
ing placebo, both manufactured by BMS. The labelling
and packaging of apixaban and matching placebo will
be conducted according to Good Manufacturing
Practice, Good Clinical Practice and national regulatory
requirements, coordinated by the study lead pharmacy.
A password-protected restricted access electronic data-
base of all randomisation codes will be kept for emer-
gency unblinding purposes. If any participant
experiences a medical emergency where management
would be improved by knowledge of the blinded treat-
ment assignment, unblinding will be available 24 hours
per day. A set of tamper-proof sealed envelopes contain-
ing the blinding code for each participant will be kept at
each site in case contact with the database server fails.
The integrity of these sealed envelopes will be periodic-
ally checked. A log of every access to the unblinding
codes will be kept and all requests for unblinding must
be clearly justiﬁed.
Treatment exposure and compliance
The study drug will be administered orally, twice daily as
2.5 mg tablets of apixaban or matching placebo, with a
dose interval of ∼12 hours. Participants will be asked to
return all the unused study drug at follow-up visits and
to self-report any missed doses of therapy. Study drug
adherence will be assessed by recording quantities of the
returned study drug at each follow-up visit. Participants
will cease using the study drug 36 months after initiation
at the baseline visit.
The study design mandates the concomitant use of at
least one advanced pulmonary vasodilator, such as an
Figure 3 Study design and assessment timeline. During the initial stages of screening, patients with SSc-PAH will be identified
via review of medical records at the multidisciplinary study sites. Formal screening assessments to confirm eligibility for the study
will occur after the patient has provided informed consent. Patients who meet all inclusion criteria and none of the exclusion
criteria will be randomised in a 1:1 ratio, stratified by study site, to receive double-blinded treatment with either 2.5mg apixaban or
placebo, twice daily for 36 months. Over the course of study treatment, participants will visit study sites at the following times
post-randomisation: 1, 3, 6, 12, 18, 24, 30 and 36 months (*=end of study visit, performed on the day of permanent cessation of
the study drug, sooner than 36 months in exceptional circumstances). Telephone follow-up will occur monthly in the first
12 months, then third-monthly thereafter, between scheduled visits until 30 days after the end of study visit (φ=37 months post-
randomisation at the latest), to ensure no adverse events have occurred and to capture all healthcare usage, including changes
to concomitant medication. SSc-PAH, scleroderma-related pulmonary arterial hypertension.
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endothelin-1 receptor antagonist (ETRA) and/or a
phosphodiesterase type-5 (PDE-5) inhibitor. However,
these therapies must be at a stable dose for at least
2 months prior to baseline. Permissible concomitant
medication includes diuretic therapy, provided that a
stable dose was maintained for at least 1 month prior to
baseline; one antiplatelet agent will be allowed at the
physician’s discretion. However, the combination of clo-
pidogrel or ticagrelor and aspirin is not allowed due to
increased risk of bleeding.51 Prohibited concomitant
medications from 1 month prior to baseline until study
drug cessation include any investigational drug other
than the study drug; oral or subcutaneous anticoagula-
tion with warfarin, apixaban, rivaroxaban, dabigatran,
enoxaparin, dalteparin or heparin. Participants must not
be receiving continuous intravenous infusion of epopros-
tenol or iloprost for PAH at baseline or be planned to
initiate this therapy within the next 3 months. However,
the following exceptions may apply following study initi-
ation: (1) the study drug may be temporarily suspended
to receive prophylactic anticoagulation during a thera-
peutic or surgical procedure if this is deemed in the par-
ticipant’s best interest; and (2) addition of intravenous
epoprostenol to oral advanced PAH therapy for partici-
pants in the modiﬁed New York Heart Association/
WHO (NYHA/WHO) functional class (FC) IV failing
ETRAs and PDE-5 inhibitors.35 Short-term treatment
with IV prostacyclin for severe Raynaud’s phenomenon
or digital ulcers may be administered at any time during
the study without constituting a clinical worsening event
(CWE).
Concomitant medications will be monitored closely
from 1 month following the baseline visit. Participants
will be required to self-report all changes to therapy
throughout the study treatment period using a health-
care usage diary. Initiation of any new PAH-speciﬁc treat-
ment or a dose increase of such a drug without
adjudicated clinical worsening of PAH is strongly dis-
couraged during the study period. If continued adminis-
tration of the study drug is believed to be contrary to
the best interests of the participant (ie, adverse event,
diagnostic or therapeutic procedure, laboratory abnor-
malities, pregnancy, unblinding or withdrawal of
consent), interruption or permanent discontinuation of
the study drug is mandated. Participants will resume the
study drug as long as the investigator feels it is safe for
them to do so and no more than 8 weeks of study treat-
ment has been missed. Participants who prematurely dis-
continue the study drug for any reason will not be
replaced and, unless they withdraw consent, will con-
tinue to be followed up six-monthly until 36 months
from baseline.
Study assessments
The study assessment schedule is illustrated in ﬁgure 2,
starting with screening and ending with follow-up
Table 1 The SPHInX study inclusion criteria
Item Characteristics of eligible participants*
1. Male and female patients aged from 18 to 75 years inclusive
2. Scleroderma defined by the ACR/EULAR 2013 classification criteria
3. RHC at any time prior to baseline demonstrating the following haemodynamic characteristics in line with current
international guidelines for diagnosis of PAH:
i. resting mPAP≥25 mm Hg and
ii. resting PVR≥3 woods units and
iii. resting PCWP or LVEDP≤15 mm Hg, or
iv. if PVR cannot or has not been measured, then mPAP≥30 mm Hg with PCWP or LVEDP≤15 mm Hg
4. 6 min walk distance >50 m at screening and/or baseline
5. Other causes of PAH, in particular CTEPH, must have been previously excluded by either a V/Q scan or CTPA
6. Currently taking at least one of the ETRA or PDE-5 inhibitor medications in a stable dose for the 2 months prior to
baseline (bosentan, ambrisentan or macitentan, and/or sildenafil or tadalafil)
7. Female participants of childbearing potential must test negative for pregnancy
8. Male and female participants of childbearing potential must agree to use a highly effective method of contraception
throughout the study and for at least 28 days after the last dose of the study drug. A participant is of childbearing
potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active
9. Female participants who are not of childbearing potential must meet at least one of the following criteria:
i. Have undergone documented hysterectomy and/or bilateral oophorectomy, or
ii. Have medically confirmed ovarian failure, or
iii. Achieved postmenopausal status, defined as cessation of regular menses for at least 12 consecutive months with
no alternative pathological or physiological cause and have a serum follicle-stimulating hormone level within the
laboratory’s reference range for postmenopausal females
*All items must be present for eligibility in the clinical trial.
ACR, American College of Rheumatology; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, CT pulmonary angiogram;
ETRA, endothelin-1 receptor antagonist EULAR, European League Against Rheumatism; LVEDP, left ventricular end diastolic pressure;
mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PDE-5,
phosphodiesterase type-5; PVR, pulmonary vascular resistance; RHC, right heart catheterisation; V/Q, ventilation/perfusion.
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30 days after permanent cessation of the study drug.
Additional visits may also take place at any time during
the treatment period in case of a suspected CWE.
Screening assessments to conﬁrm study eligibility may
occur at any time prior to randomisation, or be com-
pleted on the same day as the baseline visit. Adverse
event surveillance is prioritised at follow-up assessments.
With reference to their healthcare usage diary, partici-
pants will be required to self-report all healthcare usage
(ie, visits to healthcare/allied health practitioners and
hospitalisations), side effects and pregnancy test results
if applicable. Data collection requirements over the dur-
ation of the study are described in table 3. All data col-
lected will be entered de-identiﬁed into a customised
electronic case report form, created on the REDCap
platform, that is password protected and stored securely
on the central server at St Vincent’s Hospital
Melbourne. Hard copies of source documents will be
retained for 5 years following the end of the study.
The 6 min walk test (6MWT) will be performed in a
standardised, non-encouraged fashion, measuring the
walking distance covered by the patient during a 6 min
period followed immediately by the Borg dyspnoea
index, which rates dyspnoea severity on a visual analogue
scale from ‘0’ to ‘10’.55 The following validated HRQoL
questionnaires will be completed by the patient: the
Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36),56 the scleroderma-modiﬁed Stanford
Health Assessment Questionnaire (sHAQ)57 58 and the
Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR).59 The 6MWT and HRQoL questionnaires
will be omitted from visit 2 (1 month post-randomisa-
tion), which will serve as an abridged safety assessment
only, unless there is a suspected CWE.
Serum and platelet-free plasma samples collected at
baseline, 6-month and 24-month follow-up visits will be
stored at −80° C for the N-terminal prohormone of the
B-type natriuretic peptide (NT-proBNP) assay and
Table 2 The SPHInX study exclusion criteria
Item Characteristics of ineligible participants*
1. Pulmonary hypertension due to any other cause than SSc
2. Moderate or severe obstructive lung disease, ie, FEV1/FVC ratio <70% and FEV1<65% of predicted value after
bronchodilator administration
3. Moderate or severe restrictive lung disease, ie, FVC<70% of predicted value, provided that the HRCT scan
demonstrates moderate-to-severe changes of ILD, or FVC<60% of predicted value, regardless of the HRCT result
4. Moderate or severe hepatic impairment (ie, Child-Pugh class B or C)
5. Documented left ventricular dysfunction (ie, ejection fraction <45%)
6. Severe renal insufficiency (estimated creatinine clearance <25 mL/min, or serum creatinine >200 µmol/L)
7. Receiving any investigational drugs within 1 month prior to or at baseline
8. Receiving continuous intravenous epoprostenol or iloprost at baseline or have planned to initiate this therapy within the
next 3 months
9. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study
requirements
10. Life expectancy due to another condition of <12 months
11. Females who are breast feeding or pregnant (positive pre-randomisation serum pregnancy test) or plan to become
pregnant during the study
12. Known hypersensitivity to drugs of the same class as the study drug, or any of the excipients of the drug formulations
13. Gastrointestinal tract bleeding in the past 12 months due to GAVE or unexplained iron deficiency anaemia (in the past
12 months)
14. Haemoglobin <100 g/L at screening
15. Participants at significant risk of falls in whom anticoagulation would be inappropriate
16. Participants who have received any oral or subcutaneous anticoagulants (eg, warfarin, apixaban, rivaroxaban,
dabigatran, enoxaparin, dalteparin or heparin) for more than 3 months since the diagnosis of PAH
17. Participants with a prosthetic valve who require long-term oral anticoagulation.
18. Participants who are currently in atrial fibrillation.
19. Participants with PAH not on either an ETRA or PDE-5 inhibitor
20. Participants with known bleeding disorders and/or platelet count <100 at screening and/or INR>1.2 at screening.
21. Brain, spinal or eye surgery within the past 1 month
22. Uncontrolled systemic hypertension defined as either systolic blood pressure ≥180 mm Hg or diastolic blood pressure
≥110 mm Hg at screening
23. Documented episode of either pulmonary embolus or deep venous thrombosis since diagnosis of PAH
24. Participants with a current, or active in the past 1 month, major bleed that is life-threatening, causes chronic sequelae
or consumes major healthcare resources, as defined by the International Society on Thrombosis and Haemostasis
*Participants must not meet any of the exclusion criteria for eligibility in the clinical trial.
ETRA, endothelin-1 receptor antagonist; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GAVE, gastric antral vascular
ectasiae; HRCT, high resolution CT; ILD, interstitial lung disease; INR, international normalised ratio; PAH, pulmonary arterial hypertension;
PDE-5, phosphodiesterase type-5.
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exploratory biomarker testing.60 61 Factor Xa levels in
platelet-free plasma specimens will also be compared
between baseline and 6 months to reﬂect bioavailability
of apixaban in the treatment group.62 Anti-factor Xa
assays and biomarker assays will be performed for all
samples in triplicate, in a single laboratory, at the conclu-
sion of the study.
Outcome measures
In line with the Task Force on Endpoints and Clinical
Trial design recommendation for phase III trials at the
Fourth World Symposium on pulmonary hypertension
in Dana Point, California,63 a composite primary end
point will be employed, providing measurable para-
meters to support an independent adjudication of ‘time
to clinical worsening’. The primary end point will be
time from randomisation up to 36 months to the ﬁrst
adjudicated CWE from the composite parameters listed
in table 4. CWEs will be adjudicated in a blinded fashion
by an end point adjudication committee consisting of
four of the investigators (MN, WS, DP, SMP) who will
adjudicate each event independently and then meet to
discuss any that were not unanimously agreed on. The
study drug will be continued in a blinded fashion after a
CWE is adjudicated, to enable quantiﬁcation of the total
number of CWEs during the study period as a secondary
end point.
Selection of secondary end points was informed by
Expert Panel recommendations for a ‘core set’ of
outcome measures to be used in clinical trials of new
therapies in SSc-PAH.64 Secondary efﬁcacy end points
include all-cause mortality; absence of worsening in the
NYHA/WHO functional class; change in 6MWD and the
Borg dyspnoea index; change in the SF-36, sHAQ and
CAMPHOR questionnaire subscales. Secondary end
point comparisons will be evaluated from baseline to
each of the 12-month, 24-month and 36-month follow-up
time points, adjusted for time since diagnosis of PAH.
The last valid post-baseline value will be carried forward
to compensate for any missing values at each time point.
Safety and tolerability end points will comprise
treatment-emergent adverse events (serious and non-
serious) including marked laboratory abnormalities up
to 7 days after the last study drug intake, adverse events
leading to premature discontinuation of study drug,
change from baseline to end of study in vital signs.
Health economic end points will include number per
year, and associated costs, of all-cause and PAH-related
hospitalisations and in-patient hospital days, general
practitioner, specialist visits, allied health service usage
and initiation of new medications.
In participants who discontinue the study, where pos-
sible, CWE will be captured every 6 months to the end
of 36 weeks from enrolment.
Sample size estimation
Sample size was calculated based on a comparison of
two survival curves for the primary outcome of clinical
worsening over 3 years, applying the method of
Rubinstein et al.65 This method uses median survival
rather than event rate. The following variables were used
to determine sample size: (1) α=0.05, two-sided; (2)
Table 3 Data collection requirements over the duration of the study
Participant demographics Physical examination Physical examination
Concomitant
medications
Previous and ongoing medical history Height and weight Weight Adverse event reporting
Medications history Vital signs* Vital signs* Results of urine
pregnancy test†
Criteria for scleroderma classification ECG‡ ECG‡





V/Q scan or CTPA results that
exclude CTEPH as a cause of the
PAH
Concomitant medications Concomitant medications and
adverse event reporting
HRCT results that exclude ILD 6MWT and Borg dyspnoea
index
6MWT and Borg dyspnoea
index
Echocardiography results§ HRQoL questionnaires HRQoL questionnaires
Laboratory results¶ Echocardiography results§ Echocardiography results§
6MWT and Borg dyspnoea index Specimen collection** Specimen collection**
*Vital signs comprise heart rate and blood pressure (standing and supine).
†Monthly urine pregnancy tests are required for women of childbearing potential.
‡A standard 12-lead ECG will be performed at baseline, 6 months, 24 months, clinical worsening event and end of study visits.
§Echocardiogram images will be collected where available, and data must be obtained within 2 months of baseline, 6 and 24 month visits.
¶Laboratory samples must be taken within 2 weeks of baseline including full blood count, liver function, renal function, INR, and serum
pregnancy test or follicle-stimulating hormone levels for female participants only.
**Serum and platelet-free plasma samples will be stored for biomarker testing.
6MWT, 6 min walk test; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, CT pulmonary angiogram; HRCT, high resolution
CT; HRQoL, health-related quality of life; ILD, interstitial lung disease; INR, international normalised ratio; NHYA/WHO, New York Heart
Association/WHO; PAH, pulmonary arterial hypertension; RHC, right heart catheterisation; V/Q scan, ventilation perfusion scan.
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β=0.2 (power 80%); (3) difference to be detected
expressed as an HR of placebo:treatment=2.0, based on
previous Australian observational data, but reduced by
60% to provide a more conservative estimate for the pur-
poses of an RCT;19 (4) control group median
survival=45.6 months also based on previous Australian
observations;19 (5) ratio of participants randomised to
control and experimental groups=1:1; (6) block random-
isation stratiﬁed according to 13 centres; (7) duration of
recruitment=24 months; (8) duration of follow-up=36
months; (9) expected attrition=10%. However, substan-
tial loss to follow-up is unlikely as trial participants are
required to attend for regular review to continue receiv-
ing PAH therapy subsidised under the Pharmaceutical
Beneﬁt Scheme (PBS). Based on these assumptions, it is
expected that 65 events will be observed in this study
and a total sample size of 170 participants (85 per arm)
is required.
Statistical analyses
The hypothesis to be tested is: null hypothesis (H0)=the
distribution of the primary end point is the same in the
treatment groups; alternative hypothesis (H1)=the distri-
bution of the primary end point in the placebo group
differs from the distribution in the active group. The
ratio of the hazards of a CWE in the two groups is not
expected to change over time. Therefore, the use of
methods requiring proportional hazards is considered
appropriate. The main analyses for the primary and sec-
ondary end points will test the null hypothesis by means
of the log-rank and Wilcoxon tests, performed in the
intention-to-treat population, which includes all partici-
pants randomised. No adjustment for covariates is
planned for the primary analysis. However, in order to
evaluate the robustness of results, the primary end point
will also be analysed on the per-protocol set, with 80%
used as the cut-off to deﬁne an adherent patient.
Supportive analyses will be conducted using appropriate
covariates (eg, the date PAH was ﬁrst diagnosed by right
heart catheterisation (RHC), the start date of concomi-
tant PAH medications and combination PAH therapy) in
a Cox regression model.
The time to occurrence of the ﬁrst CWE up to 30 days
after the last study drug intake will be described by the
Kaplan-Meier survival curves. The HR of placebo:treat-
ment with two-sided 95% CIs of the event-free propor-
tion estimates at relevant time points will be presented
for each treatment group in graphical and tabular form,
in addition to descriptive statistics to summarise patient
and disease characteristics. No imputation method will
be used for the primary end point and if there is a
missing assessment (eg, no conﬁrmatory 6MWT or
NYHA/WHO FC) for a CWE; the end point adjudica-
tion committee will be responsible for qualifying or dis-
qualifying such events before primary end point analysis.
Patients without a CWE permanently discontinuing treat-
ment will be censored 30 days after study treatment dis-
continuation or date of last contact.
Differences in baseline characteristics of patients in
the apixaban and control arms will be compared using
univariate methods (χ2, t-tests and Mann-Whitney tests).
Univariate and multivariable methods (logistic and
linear regression) will be used to compare differences in
echocardiographic parameters, 6MWD, NYHA/WHO
FC, NT-proBNP level and HRQoL in the apixaban and
control arms at 1, 2 and 3 years. Covariates included in
multivariable analyses will include speciﬁc PAH therapy,
cardiovascular medications and immunosuppressives.
Sensitivity analyses will be performed to evaluate the
effect of poor treatment adherence and loss to follow-up
in patients whose fate is unknown at the end of the
study. No interim efﬁcacy analyses are planned at this
stage. However, a planned re-estimation of the sample
size may be performed prior to the expected closure of
Table 4 Definition of measurable composite primary end point parameters
Item Possible clinical worsening events
1. Death (all-cause mortality).
2. Hospitalisation for worsening of PAH due to either:
i. Need for lung transplantation or balloon atrial septostomy, or
ii. Initiation of parenteral (subcutaneous and intravenous) prostanoid therapy or chronic oxygen therapy
3. Disease progression defined by the combination of at least two of the following components:
i. Reduction from baseline in 6MWD by 15%, confirmed by two consecutive 6MWTs carried out on different days,
ideally within 2 weeks of one another
ii. Worsening of PAH symptoms included at least one of the following parameters:
a). Either an increase from baseline in the NYHA/WHO functional class (except for participants already in functional
class IV), or
b). Appearance/worsening of signs/symptoms of right heart failure
iii. Need for additional PAH-specific therapy that may include inhaled prostanoids, PDE-5 inhibitors, ETRAs or
intravenous diuretics
Any of the above singular events, or combinations of events, may be adjudicated as clinical worsening events within the composite primary
end point for the first such event, or as a secondary efficacy end point for subsequent events.
6MWD, 6 min walk distance; 6MWT, 6 min walk test; ETRA, endothelin-1 receptor antagonist; PAH, pulmonary arterial hypertension; PDE-5,
phosphodiesterase type-5.
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recruitment, based on the observed blinded event rate
in the composite end point.
Predeﬁned subgroup analyses include a comparison of
efﬁcacy and safety in incident versus prevalent PAH,
limited versus diffuse SSc disease subtypes and according
to the autoantibody proﬁle (anti-centromere anti-
nuclear antibody vs anti-topoisomerase antibody). All
statistical analyses will be performed by a biostatistician
using STATA software.
Cost-effectiveness analysis
On completion of the RCT, a health economic analysis
will be undertaken to determine the incremental cost-
effectiveness ratio, in terms of ‘net costs’ per unit of
‘health gain’. Net costs will comprise the costs of treat-
ment with apixaban and advanced PAH therapies for
the duration of life-years gained, minus costs saved from
hospitalisation and health service usage in the same
3-year time period. In order to enable this type of ana-
lysis, we will collect detailed usage data for medications,
primary care, outpatient consultations, emergency
department and elective hospitalisations, through par-
ticipant health service usage diaries, questionnaires
administered at study contact and source databases of
the participating hospitals. Since actual costs of health
service usage are not recorded, in cost-effectiveness ana-
lysis, we are making the assumption that the unit cost
assigned to each service in the Medicare Beneﬁts
Schedule (MBS) is an accurate estimate of true costs.
Collection of time-to-event data and HRQoL data will
enable calculation of quality-adjusted life years (QALYs)
gained by the inclusion of anticoagulation therapy.
Depending on the ﬁndings of the initial cost-
effectiveness analysis, further economic modelling
beyond 3 years, using the Markov approach, may be
required.
We will be applying a 5% annual discount rate to pro-
jected future costs and beneﬁts. We will undertake sensi-
tivity analyses to test the robustness of our
cost-effectiveness results, and to identify key input para-
meters to which the results are most sensitive. Both
‘one-way’ sensitivity analyses and ‘multi-way’ probabilistic
sensitivity analyses will be undertaken.
Ethics, safety monitoring, auditing and access to data
Ethical approval of this trial has been acknowledged by
the Governance ofﬁces of all hospitals involved in the
trial (Fiona Stanley Hospital, Gold Coast University
Hospital, Liverpool Hospital, Monash Health, Royal
Adelaide Hospital, Royal Hobart Hospital, Royal Prince
Alfred Hospital, The Alfred Hospital and The Queen
Elizabeth Hospital). The ﬁndings of this RCT are to be
published in open access journals, with none of the par-
ticipants identiﬁable.
An independent Data and Safety Monitoring Board
(DSMB), comprising a rheumatologist, haematologist,
cardiologist and gastroenterologist, will review unblinded
safety and tolerability data at three-monthly intervals to
ensure safety of participants for the duration of the
study. Members of the DSMB are independent of the
study investigators and are free of competing interests. A
formal DSMB charter has been produced for this study.
The randomisation code will not be broken and made
available to investigators, including the study statistician,
until after data analysis is complete.
The project coordinator based at St Vincent’s Hospital
Melbourne will audit the trial conduct and data entry
every 3–4 months and will undertake site visits. At this
stage, no independent audit of trial conduct is planned
but would occur at the request of the DSMB or regula-
tory bodies.
Only the lead chief investigator, trial coordinator and
biostatistician will have access to the ﬁnal unblinded trial
data set for the purpose of analysis and dissemination of
the ﬁndings from this study. None of these team
members will have access to unblinded trial data prior to
the completion of the study.
Communication with investigators and dissemination
of findings
Any protocol modiﬁcations such as changes to eligibility
criteria and analysis plans will be communicated by the
lead chief investigator (MN) to the principal and asso-
ciated investigators, and affected trial participants,
through personal communication including emails and
teleconferences and circulation of written documents
including an amended study protocol. Authorship of
papers arising from this study will be based on contribu-
tion to the study including intellectual content.
Study limitations
Limitations of this study include the inclusion of patients
with PAH of varying durations and not exclusively inci-
dent cases, as well as the use of self-reported health
service usage in cost-effectiveness analysis. In addition,
in this study, indirect costs are not quantiﬁed.
DISCUSSION
The design of this clinical trial was not without its chal-
lenges. Numerous studies have demonstrated that sur-
vival in SSc-PAH declines precipitously over the ﬁrst
3 years following diagnosis and thereafter plateaus, with
an overall median survival of 5 years.19 21 22 42 66
Furthermore, registry studies have shown that prevalent
cohorts of patients with PAH have better overall survival
than incident cohorts, suggesting that there may be sur-
vivor bias in patients with long-standing PAH.19
Therefore, in an RCT of a novel therapy for SSc-PAH
where the end point is a combination of mortality and
clinical worsening, it would be ideal to limit enrolment
to those with <3 years’ duration since diagnosis of PAH
on RHC. However, given the low disease prevalence, this
restriction could limit enrolment of an appropriate
sample size in a timely manner. Despite these more gen-
erous inclusion criteria, the recruitment of a sufﬁcient
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number of patients to power this clinical trial remains
the biggest challenge to its timely completion. The inves-
tigators are currently in the process of enlisting more
recruitment sites to meet sample size requirements.
Since the novel oral anticoagulants are unable to be
readily reversed, safety considerations were of utmost
importance to study design. The overall drug safety
proﬁle indicates that apixaban is generally well tolerated
with an elimination half-life of 12 hours.39 For stroke
prevention in atrial ﬁbrillation, apixaban administered
in a ‘full dose’ (5 mg two times a day) has been demon-
strated to be superior to warfarin for stroke prevention
(p=0.01), with lower risk of bleeding (p<0.001).47
Similarly, there is emerging evidence that apixaban
administered in ‘low dose’ (2.5 mg two times a day) may
yield comparable efﬁcacy to full-dose apixaban in
certain clinical settings, such as thromboprophylaxis
postarthroplasty or treatment of venous thromboembol-
ism, with no increased risk of bleeding.45 46 52
Furthermore, in acute coronary syndromes, full-dose
apixaban demonstrated a 2.45-fold increased risk of
bleeding compared with placebo (p=0.005), whereas an
increased risk of bleeding was not observed with
low-dose treatment (p=0.09).53 Therefore, in our study,
treatment comprising ‘low-dose’ apixaban should offer
safety comparable to placebo, without compromising
efﬁcacy.
While a comparison with warfarin would have been
interesting, from a practical and safety point of view, this
was not possible. First, SSc-PAH is an infrequent condi-
tion and the addition of a third arm to the study would
have increased sample size requirements, posing a
serious threat to the feasibility of this study.
Furthermore, two recently published studies have cast
doubt over the safety of warfarin relative to its potential
efﬁcacy in SSc-PAH, suggesting that this treatment may
in fact be harmful in this group of patients.29 30 Possible
reasons for this include the presence of SSc disease fea-
tures such as gastrointestinal tract hypomotility and bac-
terial overgrowth affecting the absorption of warfarin,
and the presence of gastric antral vascular ectasia and
intestinal telangiectasia, which place patients at risk of
gastrointestinal bleeding. For these reasons, as well as
those discussed earlier, we have not included a warfarin
arm in this trial.
Non-anticoagulant effects of heparins have been
described.67 The potential of such actions is currently
being investigated for the novel anticoagulants, further
supporting our choice of anticoagulant in this study.68
The clinical impact of this study is likely to be realised
in the near term and the scope for cost-savings from
reduced need for hospitalisations is considerable. Owing
to the high cost of pharmacotherapy in SSc-PAH, it was
important to build a health economic analysis into this
study to determine cost-effectiveness of adjunct anticoa-
gulation. If anticoagulant therapy is successful at
prolonging life in SSc-PAH, patients will spend a greater
period of time on costly advanced PAH-speciﬁc therapies
(typically approaching $A40 000 per drug, per patient
year).69 70 Therefore, HRQoL outcomes must be
balanced against these costs. In Australia, there is no
ofﬁcial threshold for incremental cost-effectiveness
ratios, although $A50 000 per QALY saved is commonly
used. The WHO recommends the use of gross domestic
product per capita as a starting point to consider cost-
effectiveness thresholds for a country, which for
Australia at present is ∼$A88 000.71
This study seeks to determine the efﬁcacy of a novel
therapy with the goal of improving survival in a disease
with very high short-term mortality. Until now, there
have been no published RCTs of anticoagulation in
SSc-PAH and there are no other trials currently regis-
tered in the WHO trials portal. Blinding of treatment
assignment is an innovative feature of our study design
as the majority of oral anticoagulation studies have been
open label. Positive ﬁndings in this study may provide a
rationale for further studies of factor Xa inhibition in
other pulmonary vascular diseases, including iPAH.
Thus, positive ﬁndings may have far-reaching implica-
tions beyond SSc. If the ﬁndings are negative, patients
will be spared the potential risk, inconvenience and cost
of anticoagulation. Since 30% of patients with SSc-PAH
are being anticoagulated at present in clinical practice,19
this presents a unique situation where a negative study
may be as important in terms of changing practice as a
positive study. Regardless of the outcome, our study has
the potential to redeﬁne the standard of care in a
disease entity where there is much uncertainty.
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